Silexion Therapeutics has shed nearly half its market value in a single week, while short sellers are building positions at the fastest pace in months — and a fresh earnings event arrives in just days.
The week's most striking development is how hard the stock has moved. SLXN closed Friday at $0.289, down 42% on the day and 45% for the week. Over the past month the decline reaches 72%. On Thursday the company announced the exercise of warrants covering nearly two million shares at $0.50 — well above the current price — which likely added immediate dilution pressure to an already fragile tape.
Short positioning has accelerated sharply into the decline. Estimated short shares have more than doubled over the past month, rising 121% to approximately 91,200 shares as of May 14. The weekly build of 62% is the most aggressive stretch in the data window going back to early April, when short interest was running closer to 44,000 shares. Despite that acceleration, the borrow market remains loosely set up. Cost to borrow is just 1%, down from above 2.4% in early April, and availability is ample — the lending pool is far from stressed. The short score has moved up in tandem, climbing from around 33 earlier in May to 44.2 by the 14th, though it remains well below any historical extreme for this stock, and the utilization rank places it in the 29th percentile versus peers. The setup looks more opportunistic than structurally driven — shorts appear to be leaning into the price collapse rather than initiating a technically squeezed position.
On the fundamental side, the picture is thin. The only analyst on record is a Buy initiation from Litchfield Hills in December 2025, with a $6.00 price target. That target is now more than 20 times the current market price — a gap so large it reflects either a vastly changed fundamental outlook or, more likely, a coverage that predates the company's current distress. Given the staleness and the magnitude of the mismatch, that target carries little informational value today. The company's enterprise value is negative, consistent with a micro-cap biotech burning cash before any meaningful revenue base. Scientifically, there has been activity: Silexion published data this week showing increased MHC Class I surface expression in its SIL204 immuno-oncology trial, and GMP batch manufacturing for a planned Phase 2/3 LAPC trial began in mid-May. These are early milestones, but they have done nothing to arrest the price collapse.
The insider record adds a cautious data point. The Chief Scientific Officer sold approximately 22,800 shares at $1.36 in late March — a modest transaction in dollar terms ($31,000), but notable for its direction. No insider purchases appear in the 90-day window.
The earnings history offers a mixed read for what comes next. The four most recent events produced one-day moves of −6%, +10%, −3%, and −9% respectively. The five-day drift has consistently been negative in three of four cases, ranging from −5% to −15%. With Q1 EPS reported after Friday's close at −$0.85, beating the −$1.29 estimate by a wide margin, and the next scheduled earnings call set for May 20, the focus turns to what management says about the SIL204 trial timeline, the warrant overhang, and the cash runway. Peer LTRN gained 50% on the week while SANA and ENSC fell 13% and 20% respectively — the biotech micro-cap space is highly bifurcated, and SLXN is firmly in the losing cohort.
The May 20 call is the clearest near-term event to watch — specifically whether the Q1 beat and the SIL204 data translate into any management commentary that stabilises the dilution narrative.
See the live data behind this article on ORTEX.
Open SLXN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
